Recently, the Recombinant Human nsIL12 Oncolytic Adenovirus Injection has obtained the approval by the NMPA for the clinical trial of Class I new drugs. The injection was jointly developed by the research team of Prof. Wang Pengju and Academician Nick Lemmon from the Sino-British Molecular Oncology Research Center of ZZU, and the International Joint Research Center of National Cell and Gene Therapy, and Beijing BioTTT Co., Ltd.